DocuSign: UBS raises PT to $85, maintains Neutral rating.

DocuSign: UBS raises PT to $85, maintains Neutral rating.

UBS Group has updated its price target for DocuSign (DOCU) to $85, maintaining a Neutral rating for the stock. This move comes as part of a broader review of the company's financial outlook and market conditions [1].

The updated price target represents a significant increase from the previous target set by UBS, which was not specified in the provided materials. The Neutral rating indicates that UBS analysts believe the stock's performance is expected to be in line with the broader market, neither outperforming nor underperforming significantly.

DocuSign has been the subject of various analyst reviews in recent months, with a majority of analysts maintaining a Hold rating. UBS's latest update aligns with this consensus, suggesting a cautious approach to the stock's prospects. The current consensus rating for DOCU is Hold, with 12 analysts giving a Hold rating and 4 analysts giving a Buy rating [1].

Analysts have forecasted an average price target of $90.15 for DOCuSign over the next 12 months, with a high forecast of $124.00 and a low forecast of $70.00. This average price target represents an expected upside of 18.54% from the current price of $76.05 [1].

Investors should closely monitor DocuSign's financial performance and any further updates from UBS or other analysts to make informed investment decisions. The stock's Neutral rating and the updated price target suggest a balanced outlook, indicating that the company is expected to perform in line with market conditions but may not offer significant upside or downside potential.

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/DOCU/forecast/